Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Incyte Corporation (INCY)
Incyte Corporation stock price live, this page displays NASDAQ INCY stock exchange data. View the INCY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Incyte Corporation real time stock price chart below.
What Is the Incyte Corporation Stock Price Today?
The Incyte Corporation stock price today is 117,59.
What Is the Stock Symbol for Incyte Corporation?
The stock symbol for Incyte Corporation is "INCY."
What Stock Exchange Does Incyte Corporation Trade On?
Incyte Corporation is listed and trades on the NASDAQ stock exchange.
Is Incyte Corporation a Good Stock to Buy?
Determining whether Incyte Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INCY quote. (ISIN: US45337C1027)
What Is the Incyte Corporation Stock Price Today?
The Incyte Corporation stock price today is 117,59.
What Is the Stock Symbol for Incyte Corporation?
The stock symbol for Incyte Corporation is "INCY."
What Stock Exchange Does Incyte Corporation Trade On?
Incyte Corporation is listed and trades on the NASDAQ stock exchange.
Is Incyte Corporation a Good Stock to Buy?
Determining whether Incyte Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INCY quote. (ISIN: US45337C1027)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
117.27
121.26
52 wk Range
89.25
132.60
INCY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
117.27121.26
52 wk Range
89.25132.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INCY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
131.08
Upside
+11.47%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
8 analysts have revised their earnings downwards for the upcoming period
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro- Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
13 Buy
14 Hold
1 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 131.08
(+11.47% Upside)
Incyte Corporation SWOT Analysis
Patent Cliff Looms | Incyte faces a $3 billion patent cliff by 2029, primarily due to Jakafi's loss of exclusivity, driving urgent need for new revenue streams |
Pipeline Progress | Explore Incyte's diverse pipeline, including promising drugs like povorcitinib, with potential to generate $600 million in hidradenitis suppurativa alone |
Market Valuation | Analyst consensus maintains a moderate buy, with price targets ranging from $52 to $96, reflecting varied views on Incyte's growth potential |
Strategic Expansion | Learn about Incyte's ambitious plan to launch ten new products by 2030, aiming to offset Jakafi's patent expiration and diversify revenue |
Incyte Corporation Earnings Call Summary for Q3/2026
- Incyte Q3 2026 revenue hit $1.56B, beating estimates by $90M; adjusted EPS loss of $3.60 missed by $0.07. Shares fell 1.55% in premarket.
- OPZELURA sales surged 36% YoY to $255M; core business ex-Jakafi grew 30% to $490M, targeting $3-4B by 2030 to reduce Jakafi dependence.
- Company raised FY 2026 guidance: OPZELURA to $1.1-1.12B, total net sales to $5.21-5.30B, reflecting broad portfolio strength.
- R&D expense jumped 254% YoY to $1.79B due to $1.23B Vega acquisition charge; six Phase III programs advancing across hematology-oncology.
- Key catalysts: povorcitinib U.S. approval expected Q1 2027, tafasitamab FDA decision Q1 2027, multiple late-stage readouts through H1 2027.
Last Updated: 2026/10/29, 16:30
Read Full TranscriptEarnings
Latest Release
Oct 29, 2026
EPS / Forecast
-3,60 / -3,53
Revenue / Forecast
1,56B / 1,47B
Compare INCY to Peers and Sector
Metrics to compare | INCY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINCYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 59.4x | 23.4x | −0.3x | |
PEG Ratio | −0.89 | −0.44 | 0.00 | |
Price/Book | 4.2x | 2.2x | 2.6x | |
Price / LTM Sales | 4.0x | 3.1x | 2.8x | |
Upside (Analyst Target) | 11.5% | 89.0% | 67.2% | |
Fair Value Upside | Unlock | 25.5% | 10.1% | Unlock |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Incyte (INCY) Stock Price Today?
The Incyte stock price today is 117,59 USD.
What Stock Exchange Does Incyte Trade On?
Incyte is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Incyte?
The stock symbol for Incyte is "INCY."
What Is the Incyte Market Cap?
As of today, Incyte market cap is 23,97B USD.
What Is Incyte's Earnings Per Share (TTM)?
The Incyte EPS (TTM) is 2,02.
When Is the Next Incyte Earnings Date?
Incyte will release its next earnings report on Feb 09, 2027.
From a Technical Analysis Perspective, Is INCY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Incyte Stock Split?
Incyte has split 2 times.
How Many Employees Does Incyte Have?
Incyte has 2844 employees.
What is the current trading status of Incyte (INCY)?
As of Nov 04, 2026, Incyte (INCY) is trading at a price of 117,59 USD, with a previous close of 117,59 USD. The stock has fluctuated within a day range of 117,27 USD to 121,26 USD, while its 52-week range spans from 89,25 USD to 132,60 USD.
What Is Incyte (INCY) Price Target According to Analysts?
The average 12-month price target for Incyte is 131,08 USD, with a high estimate of 157 USD and a low estimate of 86 USD. 13 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +11,47% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.